It has been claimed that RBBP4 is upregulated in gliomas by targeting of the HOXA-AS2/miR-885–5p/RBBP4 axis, whereby the viability of malignant cells can be enhanced (Shou et al., 2021). This evidence concerns the gene RBBP4 and central nervous system cancer.